Promising breast cancer drug trial pulled before starting
NCT ID NCT06585969
First seen Feb 15, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This study was designed to see if the drug trastuzumab deruxtecan works better than standard CDK4/6 inhibitors for people with a specific type of advanced breast cancer (ER-positive, HER2-low, non-luminal A). The trial was withdrawn before enrolling any participants, so no results are available. It would have involved adults with metastatic breast cancer that has spread beyond the breast.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.